Apellis Pharmaceuticals Inc [APLS] stock is trading at $24.26, up 5.71%. An important factor to consider is whether the stock is rising or falling in short-term value. The APLS shares have gain 29.39% over the last week, with a monthly amount glided 32.86%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Apellis Pharmaceuticals Inc [NASDAQ: APLS] stock has seen the most recent analyst activity on May 09, 2025, when Raymond James downgraded its rating to a Outperform but kept the price target unchanged to $52 for it. Previously, BofA Securities downgraded its rating to Neutral on May 09, 2025, and kept the price target unchanged to $23. On April 29, 2025, Cantor Fitzgerald initiated with a Overweight rating and assigned a price target of $44 on the stock. Goldman downgraded its rating to a Neutral but stick to its price target of $36 on December 17, 2024. Morgan Stanley initiated its recommendation with a Equal-Weight and recommended $31 as its price target on November 21, 2024. RBC Capital Mkts started tracking with a Sector Perform rating for this stock on October 25, 2024, and assigned it a price target of $25. In a note dated October 16, 2024, William Blair initiated an Outperform rating.
Apellis Pharmaceuticals Inc [APLS] stock has fluctuated between $16.10 and $41.94 over the past year. Currently, Wall Street analysts expect the stock to reach $22 within the next 12 months. Apellis Pharmaceuticals Inc [NASDAQ: APLS] shares were valued at $24.26 at the most recent close of the market. An investor can expect a potential drop of -9.32% based on the average APLS price forecast.
Analyzing the APLS fundamentals
Apellis Pharmaceuticals Inc [NASDAQ:APLS] reported sales of 754.65M for the trailing twelve months, which represents a drop of -10.61%. Gross Profit Margin for this corporation currently stands at 0.84% with Operating Profit Margin at -0.26%, Pretax Profit Margin comes in at -0.3%, and Net Profit Margin reading is -0.31%. To continue investigating profitability, this company’s Return on Assets is posted at -0.28, Equity is -1.16 and Total Capital is -0.32. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.7.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
For context, Apellis Pharmaceuticals Inc’s Current Ratio is 3.77. On the other hand, the Quick Ratio is 3.16, and the Cash Ratio is 1.84. Considering the valuation of this stock, the price to sales ratio is 4.06, the price to book ratio is 19.59.
Transactions by insiders
Recent insider trading involved Francois Cedric, Chief Executive Officer, that happened on Jul 17 ’25 when 19725.0 shares were sold. General Counsel, Watson David O. completed a deal on Jul 16 ’25 to sell 5000.0 shares. Meanwhile, Officer Francois Cedric bought 19725.0 shares on Jul 17 ’25.
